• Co-Diagnostics announced publication of a peer-reviewed study using its Indian joint venture CoSara Diagnostics' SARAGENE high-risk HPV test.
• Follow-up biopsies identified high-grade cervical lesions or invasive cervical cancer in HPV-positive women, despite predominantly negative cytology results.
• Investigators described the findings as preliminary, citing study design and limited HPV-positive participants; larger studies are needed to confirm the results.
• The laboratory-based test is authorized for testing in India but is not available for sale in the United States.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Co-Diagnostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA84263) on October 29, 2026, and is solely responsible for the information contained therein.